Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis - Wikidata - wikimedia - TriplyDB

Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis

Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis

http://www.wikidata.org/entity/Q36062323

about

Critical appraisal of ticagrelor in the management of acute coronary syndrome Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature.Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden.Antiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerations Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor Cost-effectiveness of oral antiplatelet agents--current and future perspectives.Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.Cost-effectiveness of ticagrelor in acute coronary syndromes.Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.Pharmacogenomics of oral antiplatelet drugs.Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention.Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome.Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada.Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia.Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review.CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.

P2860

Q35660767-3C36F28B-9118-4AAB-BD22-7234F4697F07 Q35890606-8ECCE120-A08B-441E-AD75-09DA1B69675C Q36363175-3F0BD587-8F4C-48D2-9419-EB2F028BEEFD Q36754513-9E0F6F98-715E-4A73-A3E1-3C13DAB234B4 Q36807413-6061F709-1729-4DC1-96BC-6E5FAB96C753 Q37913974-FB9595B2-F00E-470B-9A11-177C0D189F47 Q38079124-6D7E29A2-25EB-41EB-9FEA-BC96AA04D708 Q38080910-D4D810A9-2C09-4B64-978A-AABA92153ECF Q38128171-8143FF64-DFE8-48C2-8851-79FE5C252C50 Q38195628-7072EF18-02CB-4EB7-92C2-41DCA3133C57 Q38347110-5C20FF96-5137-4806-AB54-9DD4ADA2148F Q38671676-948AAD99-9D75-40D0-B72B-3F3D6B49CED4 Q39262810-1DF1BEC9-2A83-4049-A07B-BEE62688C988 Q40366831-1F9945B1-84E6-4F13-BA7C-6F6FA441DAEC Q41903978-DED19627-0082-4DBC-A327-A08CAE7BBFEA Q44258281-8F223D39-D0F4-4DBA-8E07-3D66C252F005 Q45815157-3A4F8F18-43B3-404A-A13A-9A19B01DBE35 Q47093851-3E4241CB-9DBA-4B4F-9CC5-9B7D64499883 Q48910934-7F71BB3F-CD3F-4BAA-AE29-E27EA516475A

P2860

Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis

http://www.wikidata.org/entity/Q36062323

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Ticagrelor versus genotype-dri ...... a cost-effectiveness analysis

@ast

Ticagrelor versus genotype-dri ...... a cost-effectiveness analysis

@en

type

label

Ticagrelor versus genotype-dri ...... a cost-effectiveness analysis

@ast

Ticagrelor versus genotype-dri ...... a cost-effectiveness analysis

@en

prefLabel

Ticagrelor versus genotype-dri ...... a cost-effectiveness analysis

@ast

Ticagrelor versus genotype-dri ...... a cost-effectiveness analysis

@en

P1433

Q36062323-5A1A304A-28F8-4ABB-A9CC-DD98E1C8BFEA

P1476

Q36062323-2CC0EEF6-5759-4572-8FAB-C01BF12E5B61

P2093

Q36062323-051366CE-8C93-4B7B-AD13-783EE435C3D5

Q36062323-50937E92-1042-4D5F-A774-29E39DA1423B

Q36062323-B04796D8-48F4-4A16-8ACE-BE55C0EF4FCE

Q36062323-F2F92FD7-29A2-44BF-BCE7-236E9ACA3FDB

P2860

Q36062323-0130B7E5-2B8E-4FB5-938C-EE307A2DCEC7

Q36062323-0E6E7782-97F1-4C67-9BD1-0330BE652224

Q36062323-0E735858-EDEB-4277-AC5E-6246D565BA03

Q36062323-0FAC5F23-6DEA-4CA7-BF33-3713A5822569

Q36062323-113C68BE-6F42-4943-AA3F-5EF2534A8E49

Q36062323-13E4131D-A58A-4BBC-87E2-72ABEB96DAA8

Q36062323-159CA287-7694-472F-AC84-2019ACDB5609

Q36062323-221143F5-8993-4929-B902-A7470742A3D5

Q36062323-23E188E8-0961-418E-BC34-253CE8EB6868

Q36062323-251B1F6A-1B85-4A48-A2C1-5CBBD45D92E0

P304

Q36062323-8A6ED0A5-9280-4FF2-B40B-E9E0E64DBBB7

P31

Q36062323-C4828564-5074-4193-A6C7-FD158427AA07

P356

Q36062323-5DCDBBEA-B1C9-4D26-B9C4-BCA1BDADAD64

P433

Q36062323-B9668055-6B13-40AE-BDDE-2D2E3B926861

P478

Q36062323-42C700FF-9FE1-48AC-9D2E-4B84FB2A318D

P50

Q36062323-02A49356-AFB8-496C-B436-8E9A8BAAB1BE

P577

Q36062323-D73FB6CF-584F-4C1D-860F-C6C19B1DAEE8

P5875

Q36062323-1B8486E1-83A3-44A4-936E-066770ECDA76

P698

Q36062323-E178BA70-758A-47E1-BE80-7FA6D696C327

P932

Q36062323-71BE1F7E-71E0-4556-A127-D1A22194C18E

P356

J.JVAL.2010.11.012

P1433

Value in Health

P1476

Ticagrelor versus genotype-dri ...... a cost-effectiveness analysis

@en

P2093

Daniel E Jonas

http://www.w3.org/2001/XMLSchema#string

Daniel J Crespin

http://www.w3.org/2001/XMLSchema#string

Jerome J Federspiel

http://www.w3.org/2001/XMLSchema#string

Joseph S Rossi

http://www.w3.org/2001/XMLSchema#string

P2860

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:

Does clopidogrel increase blood loss following coronary artery bypass surgery?

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Effect of clopidogrel on bleeding after coronary artery bypass surgery

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation

A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone

P304

483-491

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JVAL.2010.11.012

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Andrea K Biddle

P577

2011-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51215561

http://www.w3.org/2001/XMLSchema#string

P698

21669373

http://www.w3.org/2001/XMLSchema#string

P932

3384486

http://www.w3.org/2001/XMLSchema#string